CFO Kyri K. Van Hoose Reports 9.0% Stake in Dermata Therapeutics Following Warrant Activation

Kyri K. Van Hoose, the Chief Financial Officer and Senior Vice President of Dermata Therapeutics, Inc. (DRMA), filed a Schedule 13D indicating a new 9.0% ownership stake in the company. As of the event date on May 27, 2026, Van Hoose beneficially owns 384,352 shares of common stock. This position was primarily established through a private placement transaction that occurred on December 23, 2025, where she acquired 122,549 shares and warrants for an additional 245,098 shares using personal funds. These warrants became exercisable following stockholder approval on the event date. The total beneficial ownership includes 130,423 shares of common stock, warrants for 252,972 shares, and 957 stock options. Van Hoose acquired these securities for investment purposes and maintains her role as an executive officer. The filing also notes an amendment to a previous warrant issued in January 2025, which lowered its exercise price from $12.70 to $2.04.